Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This entry describes the potential concurrent use of two individual weight loss medications: liraglutide and orlistat. Liraglutide (brand names Saxenda, Victoza) is a GLP-1 receptor agonist that works by mimicking an intestinal hormone to increase feelings of fullness and decrease hunger signals[1][7]. Orlistat (brand names Xenical, Alli) is a lipase inhibitor that blocks the digestion and absorption of about one-third of dietary fat in the gut[1][5]. While each medication is FDA-approved for weight management and has demonstrated individual efficacy[2][3][7][8], the provided information does not detail specific clinical trials or official recommendations for their combined use[5]. Theoretically, their different mechanisms of action (appetite control vs. fat absorption inhibition) could be complementary[5]. However, concurrent use may amplify common gastrointestinal side effects associated with each drug, such as nausea, vomiting, diarrhea (liraglutide) and oily discharge, increased defecation, and fatty stools (orlistat)[1][5][7]. Orlistat use requires adherence to a low-fat diet to manage these side effects[5]. Any consideration of using these medications together would require careful medical supervision.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Liraglutide + Orlistat Combination.